118 results
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
20 Mar 24
RepliCel announces a Letter of Intent for Asset Purchase Agreement
4:38pm
be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
condition. The benefits of autologous (derived from the same person) therapy (as compared to allogeneic derived from a different person) includes minimized … intended benefit, or achieve benefits equal to or better than its competitor's products at the time of testing or production and, if so, its business may
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
, in controlled conditions in a laboratory. These purified, expanded cells are then reintroduced to the donor to treat a specific condition. The benefits … fail to provide its intended benefit, or achieve benefits equal to or better than its competitor's products at the time of testing or production
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Aug 23
Notice of Annual General and Special Meeting of Shareholders
5:15pm
sum payment as compensation for the loss of Mr. Buckler's entitlement to benefits up to a maximum of $100,000. Mr. Buckler resigned as the President … or director.
Pension Plan Benefits
The Company does not have any pension, defined benefit, defined contribution or deferred compensation plans
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
9 Aug 23
Statement of Executive Compensation
7:41pm
entitlement to benefits up to a maximum of $100,000. Mr. Buckler resigned as the President and CEO of the Company on November 28, 2022 and his employment … as compensation or held, directly or indirectly, by the NEO or director.
Pension Plan Benefits
The Company does not have any pension, defined benefit, defined contribution or deferred compensation plans in place.
6-K
EX-99.2
r8loz82po8km2 cq
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
6-K
EX-99.2
m35w9zgws ds28nt32
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
6-K
EX-99.5
d9f4sjtwplrim6
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
20-F/A
i6bv7h3
12 Sep 22
Annual report (foreign) (amended)
6:17pm
6-K
EX-99.2
tyj 7yqmk92y
6 Sep 22
Condensed Consolidated Interim Financial Statements
12:42pm
6-K
EX-99.4
hx2rgv7 aux9uihl5hbr
7 Jul 22
RepliCel Provides Update on Private Placement
3:36pm
6-K
EX-99.1
nhqoyf0 wx8d3qiafv
7 Jul 22
Statement of Executive Compensation
1:43pm
6-K
EX-99.1
xdl05z2
30 Jun 22
Statement of Executive Compensation
11:16am
6-K
EX-99.2
mnnmjohwmhvo
30 Nov 21
Condensed Consolidated Interim Financial Statements
1:50pm
6-K
EX-99.1
yf5uqwvl31a52vwv9y
18 Nov 21
Notice of Annual General and Special Meeting of Shareholders
10:36am
6-K
EX-99.2
gcnitaxrnjc7ftdo70db
31 Aug 21
Condensed Consolidated Interim Financial Statements
1:45pm
6-K
EX-99.1
4owig
13 Aug 21
RepliCel CEO Provides Corporate Update
12:00am
6-K
EX-99.2
csemvxotq19ctivq3vm
1 Jun 21
Condensed Consolidated Interim Financial Statements
3:57pm